Active Biotech AB (FRA:BTP) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BTP Active Biotech AB FRA:BTP
30 GF Score
Price €0.41
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Debt-to-Asset?

Active Biotech AB FRA:BTP +0.86% 30 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates FRA:BTP with a GF Score™ of 30/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Active Biotech AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Active Biotech AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Active Biotech AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was €4.37 Mil. Active Biotech AB's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Active Biotech AB  (FRA:BTP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Active Biotech AB Debt-to-Asset Related Terms

Active Biotech AB Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Debt-to-Asset Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.12 0.10 0.07 0.03

Active Biotech AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.00 0.00

FRA:BTP vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Active Biotech AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Active Biotech AB Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's Debt-to-Asset falls into.


FRA:BTP
30GF Score
Active Biotech AB FRA:BTP
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Active Biotech AB's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.147 + 0.012) / 6.452
=0.02

Active Biotech AB's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 4.369
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Active Biotech AB (FRA:BTP) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Active Biotech AB and its competitors.
Is Active Biotech AB's Debt-to-Asset too high?
Active Biotech AB's current Debt-to-Asset is 0.00. Overall, Active Biotech AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Debt-to-Asset compare to VRTX and REGN?
Active Biotech AB's Debt-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Active Biotech AB and its competitors. Active Biotech AB's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.41 — trading 214.2% above its estimated fair value. The current Debt-to-Asset is 0.00. Active Biotech AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Active Biotech AB (FRA:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.41 is trading 214.2% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for FRA:BTP:

  • Debt-to-Asset: 0.00
  • GF Value™: €0.13 vs. price of €0.41 (214.2% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Active Biotech AB Business Description

Other Exchanges ACTI:Sweden0GQU:UK
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
30GF Score

Get the complete analysis for FRA:BTP

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price
€0.13
GF Value